Abstract
Two novel baculovirus-derived recombinant Theileria parva p67 constructs were tested for their vaccine potential against East Coast fever. Boran calves were immunized with a his-GFP-p67 fusion protein (GFP:p67¿SS) or with GP64:p67C, a protein fusion between a C-terminal domain of p67 and the baculovirus envelope protein GP64. Both GFP:p67¿SS and GP64:p67C induced antibodies with high ELISA titers that neutralized T. parva sporozoites with high efficiency. Upon challenge, a correlation was observed between the in vitro neutralizing capacity and the reduction in severe ECF for individual animals. A protection level upto 85% was obtained. This level of protection was achieved with only two inoculations of 100 ¿g per dose, which is a major improvement over previous recombinant p67 products
Original language | English |
---|---|
Pages (from-to) | 2791-2800 |
Journal | Vaccine |
Volume | 23 |
Issue number | 21 |
DOIs | |
Publication status | Published - 2005 |
Keywords
- theileria-parva sporozoites
- neutralizing epitopes
- monoclonal-antibody
- surface-antigen
- protection
- protein
- stocks
- immunogenicity
- immunization
- leukocytes